Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

NCT06212076 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: IPG1094

Sponsor

Nanjing Immunophage Biotech Co., Ltd